C4 Therapeutics (CCCC) Revenue (2019 - 2026)

C4 Therapeutics' Revenue history runs 8 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Revenue fell 15.0% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $34.9 million, a 12.37% decrease from a year earlier, with the FY2025 full-year figure at $35.9 million, up 1.02% from the prior year.
• Revenue eased to $6.2 million in Q1 2026 per CCCC's latest filing, from $11.0 million in the prior quarter.
• Across five years, Revenue topped out at $15.4 million in Q3 2024 and bottomed at $2.7 million in Q2 2023.
• The 5-year median for Revenue is $6.8 million (2022), against an average of $7.6 million.
• Across the five-year window, Revenue slumped 85.79% in 2022 and soared 350.68% in 2024, its largest moves.
• Year by year, Revenue stood at $2.9 million in 2022, then rose by 14.26% to $3.3 million in 2023, then soared by 58.75% to $5.2 million in 2024, then soared by 112.79% to $11.0 million in 2025, then sank by 44.15% to $6.2 million in 2026.
• Per Business Quant, the three latest CCCC Revenue figures stand at $6.2 million (Q1 2026), $11.0 million (Q4 2025), and $11.2 million (Q3 2025).